Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection.
Neil J ShahGhassan Al-ShboolMatthew BlackburnMichael CookAnas BeloualiStephen V LiuSubha MadhavanAiwu Ruth HeMichael B AtkinsGeoffrey T GibneyChul KimPublished in: Journal for immunotherapy of cancer (2019)
Our retrospective series is one of the largest case series to report clinical outcomes among HIV, HBV and HCV patients treated with ICI therapy. Toxicity and efficacy rates were similar to those observed in patients without chronic viral infections. Viral reactivation was not observed. Tumor responses occurred in HIV patients with low CD4 T-cell counts. While prospective studies are needed to validate above findings, these data support not excluding such patients from ICI-based clinical trials or treatment.
Keyphrases
- end stage renal disease
- antiretroviral therapy
- hepatitis c virus
- human immunodeficiency virus
- hiv positive
- hiv infected
- clinical trial
- newly diagnosed
- ejection fraction
- hiv testing
- chronic kidney disease
- sars cov
- prognostic factors
- randomized controlled trial
- peritoneal dialysis
- men who have sex with men
- oxidative stress
- squamous cell carcinoma
- hepatitis b virus
- machine learning
- young adults
- data analysis
- papillary thyroid
- study protocol
- big data
- cell therapy
- deep learning
- lymph node metastasis
- case control